Behavioral and physiologic effects of genetic or pharmacologic inactivation of the substance P receptor (NK1)

Journal of Clinical Psychiatry

Volumn 63, Issue SUPPL. 11, 2002, Pages 11-17

  Santarelli, Luca ^a   Gobbi, Gabriella ^b   Blier, Pierre ^c   Hen, René ^a  

^a Howard Hughes Medical Institute   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; NEUROKININ 1 RECEPTOR; NEUROPEPTIDE; NEUROTRANSMITTER; PROTEIN C FOS; SEROTONIN; SUBSTANCE P RECEPTOR;

ANXIETY; BEHAVIOR; BRAIN REGION; DEPRESSION; DESENSITIZATION; DORSAL RAPHE NUCLEUS; DRUG MECHANISM; FEEDING; FINANCIAL MANAGEMENT; GENETIC PROCEDURES; HEALTH CARE; MAZE TEST; MOOD DISORDER; NONHUMAN; NORADRENERGIC SYSTEM; OPEN FIELD BEHAVIOR; PATHOPHYSIOLOGY; PHYSIOLOGY; PRESYNAPTIC NERVE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SEROTONINERGIC SYSTEM; STRESS; SWIMMING; UNITED STATES; VOCALIZATION;

AFFECT; ANIMALS; ANXIETY DISORDERS; AUTORECEPTORS; BEHAVIOR, ANIMAL; CORTICOSTERONE; DIAZEPAM; DISEASE MODELS, ANIMAL; FEEDING BEHAVIOR; LOCUS COERULEUS; MICE; MICE, KNOCKOUT; MORPHOLINES; MOTOR ACTIVITY; NEURONS; NOREPINEPHRINE; RAPHE NUCLEI; RECEPTORS, NEUROKININ-1; SEROTONIN; SWIMMING;

EID: 0036452457     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Campos D, Pereira JR, Reinhardt RR, et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 2001;19:1759-1767
2. Van Belle S, Lichinitser MR, Navari RM, et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer 2002;94:3032-3041
3. Mantyh PW, Hunt SP, Maggio JE. Substance P receptors: Localization by light microscopic autoradiography in rat brain using [3H]SP as the radioligand. Brain Res 1984;307:147-165
4. Arai H, Emson PC. Regional distribution of neuropeptide K and other tachykinins (neurokinin A, neurokinin B and substance P) in rat central nervous system. Brain Res 1986;399:240-249
5. Ribeiro-da-Silva A, Hokfelt T. Neuroanatomical localisation of substance P in the CNS and sensory neurons. Neuropeptides 2000;34:256-271
6. Elliott PJ. Place aversion induced by the substance P analogue, dimethyl-C7, is not state dependent: Implication of substance P in aversion. Exp Brain Res 1988;73:354-356
7. Aguiar MS, Brandao ML. Effects of microinjections of the neuropeptide substance P in the dorsal periaqueductal gray on the behaviour of rats in the plus-maze test. Physiol Behav 1996;60:1183-1186
8. Teixeira RM, Santos AR, Ribeiro SJ, et al. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. Eur J Pharmacol 1996;311:7-14
9. Krase W, Koch M, Schnitzler HU. Substance P is involved in the sensitization of the acoustic startle response by footshocks in rats. Behav Brain Res 1994;63:81-88
10. Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998;281:1640-1645
11. Culman J, Unger T Central tachykinins: Mediators of defence reaction and stress reactions. Can J Physiol Pharmacol 1995;73:885-891
12. Bannon MJ, Deutch AY, Tam SY, et al. Mild footshock stress dissociates substance P from substance K and dynorphin from Met- and Leuenkephalin. Brain Res 1986;381:393-396
13. Brodin E, Rosen A, Schott E, et al. Effects of sequential removal of rats from a group cage, and of individual housing of rats, on substance P, cholecystokinin and somatostatin levels in the periaqueductal grey and limbic regions. Neuropeptides 1994;26:253-260
14. Walker PD, Riley LA, Hart RP, et al. Serotonin regulation of neostriatal tachykinins following neonatal 6-hydroxydopamine lesions. Brain Res 1991;557:31-36
15. Shirayama Y, Mitsushio H, Takashima M, et al. Reduction of substance P after chronic antidepressant treatment in the striatum, substantia nigra and amygdala of the rat. Brain Res 1996;739:70-78
16. Rimon R, Le Greves P, Nyberg F, et al. Elevation of substance P-like peptides in the CSF of psychiatric patients. Biol Psychiatry 1984;19:509-516
17. Berrettini WH, Rubinow DR, Numberger JI Jr, et al. CSF substance P immunoreactivity in affective disorders. Biol Psychiatry 1985;20:965-970
18. Beresford IJ, Birch PJ, Hagan RM, et al. Investigation into species variants in tachykinin NK1 receptors by use of the non-peptide antagonist, CP-96,345. Br J Pharmacol 1991;104:292-293
19. Rupniak NM, Boyce S, Williams AR, et al. Antinociceptive activity of NK1 receptor antagonists: Non-specific effects of racemic RP67580. Br J Pharmacol 1993;110:1607-1613
20. Rupniak NM, Tattersall FD, Williams AR, et al. In vitro and in vivo predictors of the anti-emetic activity of tachykinin NK1 receptor antagonists. Eur J Pharmacol 1997;326:201-209
21. Rupniak NM, Carlson EC, Harrison T, et al. Pharmacological blockade or genetic deletion of substance P (NK(1)) receptors attenuates neonatal vocalisation in guinea-pigs and mice. Neuropharmacology 2000;39:1413-1421
22. Rupniak NM, Kramer MS. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol Sci 1999;20:485-490
23. Santarelli L, Gobbi G, Debs PC, et al. Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc Natl Acad Sci U S A 2001;98:1912-1917
24. Ramboz S, Oosting R, Amara DA, et al. Serotonin receptor 1A knockout: An animal model of anxiety-related disorder. Proc Natl Acad Sci U S A 1998;95:14476-14481
25. Fong TM, Yu H, Strader CD. Molecular basis for the species selectivity of the neurokinin-1 receptor antagonists CP-96,345 and RP67580. J Biol Chem 1992;267:25668-25671
26. Bodnoff SR, Suranyi-Cadotte B, Quirion R, et al. A comparison of the effects of diazepam versus several typical and atypical anti-depressant drugs in an animal model of anxiety. Psychopharmacology 1989;97:277-279
27. Hofer MA. Multiple regulators of ultrasonic vocalization in the infant rat. Psychoneuroendocrinology 1996;21:203-217
28. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: A primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977;229:327-336
29. Prince CR, Anisman H. Acute and chronic stress effects on performance in a forced-swim task. Behav Neural Biol 1984;42:99-119
30. Porsolt RD. Animal model of depression. Biomedicine 1979;30:139-140
31. Crawley JN. Exploratory behavior models of anxiety in mice. Neurosci Biobehav Rev 1985;9:37-44
32. Lister RG. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 1987;92:180-185
33. File SE. Behavioral detection of anxiolytic action. In: Elliot JM, Heal DJ, Marsden CA, eds. Experimental Approaches to Anxiety and Depression. New York, NY: John Wiley & Sons; 1992:26-44
34. Brunner D, Buhot MC, Hen R, et al. Anxiety, motor activation, and maternal-infant interactions in 5HT1B knockout mice. Behav Neurosci 1999;113:587-601
35. Silveira MC, Sandner G, Graeff FG. Induction of Fos immunoreactivity in the brain by exposure to the elevated plus-maze. Behav Brain Res 1993;56:115-118
36. Duncan GE, Knapp DJ, Breese GR. Neuroanatomical characterization of Fos induction in rat behavioral models of anxiety. Brain Res 1996;713:79-91
37. Hess US, Gall CM, Granger R, et al. Differential patterns of c-fos mRNA expression in amygdala during successive stages of odor discrimination learning. Learn Mem 1997;4:262-283
38. Haddjeri N, Blier P. Sustained blockade of neurokinin-1 receptor enhances serotonin neurotransmission. Biol Psychiatry 2001;50:191-199
39. Peyron C, Luppi PH, Fort P, et al. Lower brainstem catecholamine afferents to the rat dorsal raphe nucleus. J Comp Neurol 1996;364:402-413
40. Haddjeri N, Blier P. Effect of neurokinin-I receptor antagonists on the function of 5-HT and noradrenaline neurons. Neuroreport 2000;11:1323-1327
41. Blier P, de Montigny C, Tardif D. Effects of the two antidepressant drugs mianserin and indalpine on the serotonergic system: Single-cell studies in the rat. Psychopharmacology 1984;84:242-249
42. Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994;15:220-226